Table 4.
VEGFR inhibitors | Total ADR | Polycythemia | Hemoglobin increase | Hematocrit increase | Total AE |
---|---|---|---|---|---|
Lenvatinib | 9641 | 8 | 8 | 2 | 18 |
Pazopanib | 25,765 | 18 | 16 | 8 | 42 |
Axitinib | 10,708 | 21 | 16 | 7 | 44 |
Bevacizumab | 73,693 | 18 | 23 | 17 | 58 |
Sorafenib | 29,816 | 9 | 5 | 0 | 14 |
Sunitinib | 36,552 | 7 | 9 | 4 | 20 |
Vandetanib | 1290 | 6 | 4 | 4 | 14 |
Cediranib | 157 | 0 | 2 | 0 | 2 |
Regorafenib | 13,427 | 1 | 2 | 0 | 3 |
Semaxanib | 19 | 0 | 0 | 0 | 0 |
ADR adverse drug reaction; AE adverse event